Who are DA-3002's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo + fulvestrant, Fulvestrant combined with Pyrotinib, GB491+ Fulvestrant, HGP0904, CKD-342, CKD-843 dose#1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/da-3002.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DA-3002 — Competitive Intelligence Brief

DA-3002 (DA-3002) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Estrogen Receptor Degrader (SERD). Area: Oncology.

phase 3 Selective Estrogen Receptor Degrader (SERD) Estrogen Receptor Alpha (ERα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DA-3002 (DA-3002) — Dong-A ST Co., Ltd.. DA-3002 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating both ligand-dependent and ligand-independent signaling in hormone receptor-positive breast cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DA-3002 TARGET	DA-3002	Dong-A ST Co., Ltd.	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor Alpha (ERα)
Placebo + fulvestrant	Placebo + fulvestrant	Nanjing Chia-tai Tianqing Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Fulvestrant combined with Pyrotinib	Fulvestrant combined with Pyrotinib	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Selective estrogen receptor degrader (SERD) combined with HER tyrosine kinase inhibitor	Estrogen receptor (ER) and HER1/HER2/HER4
GB491+ Fulvestrant	GB491+ Fulvestrant	Genor Biopharma Co., Ltd.	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
HGP0904	HGP0904	Hanmi Pharmaceutical Company Limited	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-342	CKD-342	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-843 dose#1	CKD-843 dose#1	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Estrogen Receptor Degrader (SERD) class)

Chong Kun Dang Pharmaceutical · 7 drugs in this class
Hanmi Pharmaceutical Company Limited · 2 drugs in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Genor Biopharma Co., Ltd. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
AstraZeneca · 1 drug in this class
Nanjing Chia-tai Tianqing Pharmaceutical · 1 drug in this class
BeOne Medicines · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DA-3002 — Competitive Intelligence Brief. https://druglandscape.com/ci/da-3002. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab